Program overview

**Wednesday, November 22, 2023**

17:00–19:00 Registration open (Arken Building)
18:00 Opening remarks (Auditorium Armfelt)

**Thursday, November 23, 2023**

08:15–15:00 Registration open (Arken Building)
08:45–16:30 Scientific Program (Auditorium Armfelt)
18:00–20:00 Conference Dinner (Restaurant Kåren)
20:00 → Evening Program (Restaurant Kåren)

**Friday, November 24, 2023**

08:30–16:00 Registration open (Arken Building)
09:00–17:00 Scientific Program (Auditorium Armfelt & Helikon)
18:00 Sauna group visit (Arken Building)
18:15 → Informal get-together (Ravintola Koulu)
Program of oral presentations

Thursday, November 23, 2023

Auditorium Armfelt

8:45-9:00  Opening Words

What is (a) psychedelic?
Erika Dyck - What is (a) psychedelic: Historical perspectives

9:00-10:30  What is (a) psychedelic?
Vesa-Pekka Herva - Altered states of consciousness, shamanism and everyday practices in contemporary urban culture
Aleksi Hupli - Psychedelics as pharmacological technologies: instrumental drug use and politicogenic drug effects

10:30-10:45  Break

10:45-12:15  What are psychedelic experiences?
Aidan Lyon - Psychedelic Experience: Revealing the Mind
Katherine Cheung - The Narratives of Love and Psychedelics
Jukka-Pekka Heikkilä - Exploring psychedelic experiences: Insights from narrative collections in transformational festivals

12:15-13:15  Lunch

13:15-14:15  Keynote Presentation: Max Wolff - Psychedelic therapy is psychotherapy: Connecting the dots between two fields that belong together

14:15-15:00  Poster Session and Coffee Break

14:15-15:00  Therapy
Patrick Zilliacus & Heikki Vanhanen - Psilocybin in a clinical study in Finland - What have we learned in working with psilocybin to treat alcohol use disorder
Oskari Ventilä - Psychedelic-assisted psychotherapies from the viewpoint of cognitive behavioral therapy
Gustav Martling - Psychedelics, attachment & emotional regulation - How might therapist’s use of psilocybin affect their work?
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00-10:30</td>
<td>Empirical Research</td>
<td>Auditorium Armfelt</td>
<td>Jussi Jylkkä - Previous experience of psychedelics predict endorsement of idealism</td>
<td>Andreas Krabbe - Associations between psychedelic experiences, psychological flexibility and well-being</td>
</tr>
<tr>
<td>10:30-10:45</td>
<td>Break</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:45-12:15</td>
<td>Real-World Use of Psychedelics</td>
<td></td>
<td>Mika Tsupari - Glimpses of set and setting in Finland and the self-reported benefits of psychedelic use</td>
<td>Emma Kopra - Investigation of Self-Treatment with Lysergic Acid Diethylamide (LSD) and Psilocybin Mushrooms: Findings from the Global Drug Survey 2020</td>
</tr>
<tr>
<td>12:15-13:15</td>
<td>Lunch</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:15-14:15</td>
<td>Keynote Presentation: Manvir Singh - Shamanism and the Scope of Psychedelic Use</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:15-14:30</td>
<td>Break</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30-15:30</td>
<td>Trauma and Psychedelic Experiences</td>
<td></td>
<td>Eva Roussou - Through a trauma lens: A clinical perspective on the implications of trauma in psychedelic experiences and the application of trauma-informed frameworks in provision to improve safety and agency.</td>
<td>Samuli Kangaslampi - Psychedelic and traumatic experiences as pivotal mental states and transformative experiences</td>
</tr>
<tr>
<td>15:30-16:00</td>
<td>Coffee Break</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00-16:45</td>
<td>Panel Discussion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:45-17:00</td>
<td>Closing Words</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Poster Presentations

Thursday, November 23, 2023, 14:15–15:00

Julia Eklund - Psilocin esters – An investigation of synthetic feasibility, chemical, and metabolic stability

Antti Hupli - Review of MDMA-assisted therapy for moderate to severe PTSD in phase 2&3 studies and possible compassionate use in Finland

Liisa Ilkka - The effect of lysergic acid diethylamide on brain BDNF levels and Pavlovian extinction learning in mice

Joel Janhonen, Heikki Saxén, & Mikko Värttö - Digital Bioethics on Psychedelics

Petri Kajonius & David Sjöström - Reproducing the Psychedelic Experience – One of the 5 Most Meaningful Experiences in Life?

Sakari Rusanen - Psilocybin in the Treatment of Cluster Headache

Janika Ruuska - Serotonergic Mechanisms and Cognitive Flexibility in Anorexia Nervosa: Implications for Psilocybin Treatment

Ville Räisänen - Can Psychedelic Experience Reveal the Nature of the Mind?

Alku Sirén - Domesticated mysteries. What is it that allows for the growing acceptance of psychedelics?

Hilla Väyrynen - Body Image and the Bodily Self in Mystical-type Experiences